Platelet function and its clinical significance in the myeloproliferative disorders

Aliza Zeidman, Alon Horowits, Pazit Kanter, Gideon Y. Stein, Ophra Redlich, Amos Cohen, Moshe Mittelman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The present study was aimed to investigate platelet function in myeloproliferative disease (MPD) and its clinical significance. We studied 28 patients with MPD [polycythaemia vera, essential thrombocythosis (ET) and agnogneic myeloid metaplasia with myelofibrosis]. The mean platelet count was 240×109/l. Patients with platelet count less than 70×109/l were excluded. The mean bleeding time (BT) was 2.7 minutes. Only 1 patient has prolonged BT of 8 minutes (normal range 1-4 minutes). Platelet aggregation (PA) was studied with epinephrine (Epi), ADP, arachidonic acid (AA), ristocetin and collagen. Overall 22 patients (79%) patients had PA abnormality compared to 20% in the control group, 59% had impaired Epi-induced PA, 32% demonstrated reduced ADP-induced PA. Arachidonic acid, ristocetin and collagen was decreased PA in 48%, 18% and 11% respectively. Patients with polycythaemia vera and essential thrombocytosis demonstrated a similar platelet function profile as the whole MPD series with the exception of spontaneous aggregation in patients with ET (83%) which correlates with their thrombosis tendency (p <0.049). In the present study of 28 MPD patients, PA abnormalities were relatively common including bleeding and thrombotic episodes, spontaneous aggregation was significantly higher and was correlated to thrombotic events especially in ET patients.

Original languageEnglish
Pages (from-to)64-69
Number of pages6
JournalHAEMA
Volume8
Issue number1
StatePublished - Jan 2005

Keywords

  • Bleeding time
  • Essential thrombocytosis
  • Myeloproliferative disorders
  • Platelet aggregation
  • Polycythemia vera

Fingerprint

Dive into the research topics of 'Platelet function and its clinical significance in the myeloproliferative disorders'. Together they form a unique fingerprint.

Cite this